07.05.2013 - Spanish diagnostics specialist STAT-Diagnostica has secured €17m in Series B financing.
The Barcelona-based specialist for decentralised testing said it will use the proceeds to complete development of the company’s Near Patient Testing diagnostic system Diagcore and clinical validation of its first products. Led by new investor Kurma Life Sciences Partners, the round also drew participation from new investors Idinvest, Boehringer Ingelheim Venture Fund, and, Caixa Capital Risc, the venture capital division of “la Caixa” as well as existing investors Ysios Capital and Axis.
Founded in 2010, STAT-Diagnostica develops Near Patient Testing systems that simplify and reduce time to results in the growing markets of molecular diagnostics and immunodiagnostics. Its Diagcore® platform enables multiplex qPCR and immundiagnostic analyses in 15 to 30 minutes per run. The company announced that its first testing cartridges will be directed at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.
"The Series B financing is a significant milestone that will support our preparation for a European market launch in 2015,” said Jordi Carrera, CEO and co-founder of STAT-Diagnostica. As part of the Series B financing, Ysios Capital significantly increased its investment in STAT-Diagnostica to become the company’s largest shareholder.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.